News & Investors

Investor Relations

Corporate Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Stock Price

Aug 10, 2022 12:19 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
Aug 05, 2022
Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 02, 2022
Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Jul 29, 2022
Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
Aug 5, 2022
8:00 AM EDT
Forma Therapeutics Second Quarter 2022 Financial Results and Business Update
Learn more
Jun 9, 2022
2:00 PM EDT
Jefferies Healthcare Conference
Learn more
May 26, 2022
8:00 AM - 10:00 AM EDT
Forma Therapeutics R&D Day
Learn more